JSC "Froceth" is rated 3 out of 5 in the category biotechnology. Read and write reviews about JSC "Froceth". We are the first and only biotechnology company in Lithuania manufacturing advanced therapy medicinal products (ATMPs) individually for each patient. We develop our products using patients’ own tissues and cells in the manufacturing process, and by addressing the specific needs of each person. All our processes are carried out using the most advanced technologies for somatic cell therapy. We started our business in 2014, after combining the knowledge and long-standing experience of qualified biomedical doctors, molecular biologists and biotechnologists, and establishing an adipose tissue bank. In 2015 we established an ATMP manufacturing site in Vilnius. We continually keep investing in research related to the production and development of new medicinal products for use in advanced therapies, with the aim to expand the field of personalized therapy in Lithuania. The results of all the scientific research carried out by our scientists are officially published in peer-reviewed journals, and we vigorously participate in projects in collaboration with domestic and foreign biotechnology companies, tissue banks, universities and other scientific institutions. We provide tissue bank services in accordance with License No. 3635 issued by the State Health Care Accreditation Agency under the Ministry of Health. We also manufacture ATMPs in accordance with Permit No. 2. issued by the Ministry of Health. We also work with 5 more licenses that allow the production of ATMP for individual clients with a doctor’s prescription: 1) License No. 2 for dendritic cell activated with oncolysate (DLP); 2) License No. 3 for the Cytokine Induced Killer cell preparation (CIK); 3) License No. 4 for the T – Cell Vacination (TCV), 4) License No. 5 for the Proprietary Stromal Vascular Fraction (SVFP).
Company size
11-50 employees